Cargando…
Folic Acid and Creatine as Therapeutic Approaches to Lower Blood Arsenic: A Randomized Controlled Trial
BACKGROUND: The World Health Organization estimates that > 140 million people worldwide are exposed to arsenic (As)–contaminated drinking water. As undergoes biologic methylation, which facilitates renal As elimination. In folate-deficient individuals, this process is augmented by folic acid (FA)...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Institute of Environmental Health Sciences
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671237/ https://www.ncbi.nlm.nih.gov/pubmed/25978852 http://dx.doi.org/10.1289/ehp.1409396 |
_version_ | 1782404376601559040 |
---|---|
author | Peters, Brandilyn A. Hall, Megan N. Liu, Xinhua Parvez, Faruque Sanchez, Tiffany R. van Geen, Alexander Mey, Jacob L. Siddique, Abu B. Shahriar, Hasan Uddin, Mohammad Nasir Islam, Tariqul Balac, Olgica Ilievski, Vesna Factor-Litvak, Pam Graziano, Joseph H. Gamble, Mary V. |
author_facet | Peters, Brandilyn A. Hall, Megan N. Liu, Xinhua Parvez, Faruque Sanchez, Tiffany R. van Geen, Alexander Mey, Jacob L. Siddique, Abu B. Shahriar, Hasan Uddin, Mohammad Nasir Islam, Tariqul Balac, Olgica Ilievski, Vesna Factor-Litvak, Pam Graziano, Joseph H. Gamble, Mary V. |
author_sort | Peters, Brandilyn A. |
collection | PubMed |
description | BACKGROUND: The World Health Organization estimates that > 140 million people worldwide are exposed to arsenic (As)–contaminated drinking water. As undergoes biologic methylation, which facilitates renal As elimination. In folate-deficient individuals, this process is augmented by folic acid (FA) supplementation, thereby lowering blood As (bAs). Creatinine concentrations in urine are a robust predictor of As methylation patterns. Although the reasons for this are unclear, creatine synthesis is a major consumer of methyl donors, and this synthesis is down-regulated by dietary/supplemental creatine. OBJECTIVES: Our aim was to determine whether 400 or 800 μg FA and/or creatine supplementation lowers bAs in an As-exposed Bangladeshi population. METHODS: We conducted a clinical trial in which 622 participants were randomized to receive 400 μg FA, 800 μg FA, 3 g creatine, 3 g creatine+400 μg FA, or placebo daily. All participants received an As-removal filter on enrollment, and were followed for 24 weeks. After the 12th week, half of the two FA groups were switched to placebo to evaluate post-treatment bAs patterns. RESULTS: Linear models with repeated measures indicated that the decline in ln(bAs) from baseline in the 800-μg FA group exceeded that of the placebo group (weeks 1–12: β= –0.09, 95% CI: –0.18, –0.01; weeks 13–24: FA continued: β= –0.12, 95% CI: –0.24, –0.00; FA switched to placebo: β= –0.14, 95% CI: –0.26, –0.02). There was no rebound in bAs related to cessation of FA supplementation. Declines in bAs observed in the remaining treatment arms were not significantly different from those of the placebo group. CONCLUSIONS: In this mixed folate-deficient/replete study population, 12- and 24-week treatment with 800 μg (but not 400 μg) FA lowered bAs to a greater extent than placebo; this was sustained 12 weeks after FA cessation. In future studies, we will evaluate whether FA and/or creatine altered As methylation profiles. CITATION: Peters BA, Hall MN, Liu X, Parvez F, Sanchez TR, van Geen A, Mey JL, Siddique AB, Shahriar H, Uddin MN, Islam T, Balac O, Ilievski V, Factor-Litvak P, Graziano JH, Gamble MV. 2015. Folic acid and creatine as therapeutic approaches to lower blood arsenic: a randomized controlled trial. Environ Health Perspect 123:1294–1301; http://dx.doi.org/10.1289/ehp.1409396 |
format | Online Article Text |
id | pubmed-4671237 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | National Institute of Environmental Health Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-46712372015-12-16 Folic Acid and Creatine as Therapeutic Approaches to Lower Blood Arsenic: A Randomized Controlled Trial Peters, Brandilyn A. Hall, Megan N. Liu, Xinhua Parvez, Faruque Sanchez, Tiffany R. van Geen, Alexander Mey, Jacob L. Siddique, Abu B. Shahriar, Hasan Uddin, Mohammad Nasir Islam, Tariqul Balac, Olgica Ilievski, Vesna Factor-Litvak, Pam Graziano, Joseph H. Gamble, Mary V. Environ Health Perspect Research BACKGROUND: The World Health Organization estimates that > 140 million people worldwide are exposed to arsenic (As)–contaminated drinking water. As undergoes biologic methylation, which facilitates renal As elimination. In folate-deficient individuals, this process is augmented by folic acid (FA) supplementation, thereby lowering blood As (bAs). Creatinine concentrations in urine are a robust predictor of As methylation patterns. Although the reasons for this are unclear, creatine synthesis is a major consumer of methyl donors, and this synthesis is down-regulated by dietary/supplemental creatine. OBJECTIVES: Our aim was to determine whether 400 or 800 μg FA and/or creatine supplementation lowers bAs in an As-exposed Bangladeshi population. METHODS: We conducted a clinical trial in which 622 participants were randomized to receive 400 μg FA, 800 μg FA, 3 g creatine, 3 g creatine+400 μg FA, or placebo daily. All participants received an As-removal filter on enrollment, and were followed for 24 weeks. After the 12th week, half of the two FA groups were switched to placebo to evaluate post-treatment bAs patterns. RESULTS: Linear models with repeated measures indicated that the decline in ln(bAs) from baseline in the 800-μg FA group exceeded that of the placebo group (weeks 1–12: β= –0.09, 95% CI: –0.18, –0.01; weeks 13–24: FA continued: β= –0.12, 95% CI: –0.24, –0.00; FA switched to placebo: β= –0.14, 95% CI: –0.26, –0.02). There was no rebound in bAs related to cessation of FA supplementation. Declines in bAs observed in the remaining treatment arms were not significantly different from those of the placebo group. CONCLUSIONS: In this mixed folate-deficient/replete study population, 12- and 24-week treatment with 800 μg (but not 400 μg) FA lowered bAs to a greater extent than placebo; this was sustained 12 weeks after FA cessation. In future studies, we will evaluate whether FA and/or creatine altered As methylation profiles. CITATION: Peters BA, Hall MN, Liu X, Parvez F, Sanchez TR, van Geen A, Mey JL, Siddique AB, Shahriar H, Uddin MN, Islam T, Balac O, Ilievski V, Factor-Litvak P, Graziano JH, Gamble MV. 2015. Folic acid and creatine as therapeutic approaches to lower blood arsenic: a randomized controlled trial. Environ Health Perspect 123:1294–1301; http://dx.doi.org/10.1289/ehp.1409396 National Institute of Environmental Health Sciences 2015-05-15 2015-12 /pmc/articles/PMC4671237/ /pubmed/25978852 http://dx.doi.org/10.1289/ehp.1409396 Text en http://creativecommons.org/publicdomain/mark/1.0/ Publication of EHP lies in the public domain and is therefore without copyright. All text from EHP may be reprinted freely. Use of materials published in EHP should be acknowledged (for example, “Reproduced with permission from Environmental Health Perspectives”); pertinent reference information should be provided for the article from which the material was reproduced. Articles from EHP, especially the News section, may contain photographs or illustrations copyrighted by other commercial organizations or individuals that may not be used without obtaining prior approval from the holder of the copyright. |
spellingShingle | Research Peters, Brandilyn A. Hall, Megan N. Liu, Xinhua Parvez, Faruque Sanchez, Tiffany R. van Geen, Alexander Mey, Jacob L. Siddique, Abu B. Shahriar, Hasan Uddin, Mohammad Nasir Islam, Tariqul Balac, Olgica Ilievski, Vesna Factor-Litvak, Pam Graziano, Joseph H. Gamble, Mary V. Folic Acid and Creatine as Therapeutic Approaches to Lower Blood Arsenic: A Randomized Controlled Trial |
title | Folic Acid and Creatine as Therapeutic Approaches to Lower Blood Arsenic: A Randomized Controlled Trial |
title_full | Folic Acid and Creatine as Therapeutic Approaches to Lower Blood Arsenic: A Randomized Controlled Trial |
title_fullStr | Folic Acid and Creatine as Therapeutic Approaches to Lower Blood Arsenic: A Randomized Controlled Trial |
title_full_unstemmed | Folic Acid and Creatine as Therapeutic Approaches to Lower Blood Arsenic: A Randomized Controlled Trial |
title_short | Folic Acid and Creatine as Therapeutic Approaches to Lower Blood Arsenic: A Randomized Controlled Trial |
title_sort | folic acid and creatine as therapeutic approaches to lower blood arsenic: a randomized controlled trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671237/ https://www.ncbi.nlm.nih.gov/pubmed/25978852 http://dx.doi.org/10.1289/ehp.1409396 |
work_keys_str_mv | AT petersbrandilyna folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial AT hallmegann folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial AT liuxinhua folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial AT parvezfaruque folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial AT sancheztiffanyr folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial AT vangeenalexander folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial AT meyjacobl folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial AT siddiqueabub folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial AT shahriarhasan folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial AT uddinmohammadnasir folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial AT islamtariqul folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial AT balacolgica folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial AT ilievskivesna folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial AT factorlitvakpam folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial AT grazianojosephh folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial AT gamblemaryv folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial |